Summary
ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case
ClearPoint Neuro's second quarter results were poor across the board, with drug delivery disposables an area of particular weakness. Delays in the ramping of preclinical services at ClearPoint's new facility have also contributed to reduced expectations for 2026. There is now regulatory clarity, though, meaning a revenue inflection as AMT-130 is commercialized is now highly likely in 2027/2028.
ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript
ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for ClearPoint Neuro (CLPT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ClearPoint Neuro Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 68,048 | $1.21M | $966,962.08 | -$247,012.92 | -20.35% |
| LN Louis Navellier NAVELLIER & ASSOCIATES Inc. | 50,000 | $340,000 | $640,000 | $300,000 | 88.24% |
| NA Nizar Araji National Bank Of Canada /FI/ | 802 | $8,995.7 | $11,412.46 | $2,416.76 | 26.87% |
| CPS Chow Pak Sun Gordian Capital Singapore Pte Ltd. | 15,500 | $276,520 | $235,290 | -$41,230 | -14.91% |
 Joseph Castro Nuveen LLC | 72,990 | $932,008.28 | $1.06M | $131,456.02 | 14.1% |
ClearPoint Neuro Inc. (CLPT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ClearPoint Neuro Inc. ever had a stock split?
ClearPoint Neuro Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Joseph Michael Burnett CEO | NASDAQ (CM) Exchange | 18507C103 CUSIP |
| US Country | 172 Employees | - Last Dividend | 27 Jul 2016 Last Split | 12 Feb 2020 IPO Date |
Overview
ClearPoint Neuro, Inc. is a prominent medical device company primarily operating in the United States, with a focus on developing and commercializing innovative platforms designed for performing minimally invasive surgical procedures in the brain. These procedures are guided by magnetic resonance imaging (MRI), ensuring precision and safety. The company, originally known as MRI Interventions, Inc., underwent a name change to ClearPoint Neuro, Inc. in February 2020, marking a new chapter in its commitment to advancing neurological interventions. Incorporated in 1998 and based in Solana Beach, California, ClearPoint Neuro has established various strategic license and collaboration agreements with notable entities such as Clinical Laserthermia Systems AB, Koninklijke Philips N.V., UCB Biopharma SRL, and the University of California and San Francisco. Additionally, it has entered into a development and license agreement with NE Scientific, LLC, further expanding its research and development capabilities in pursuit of innovative neurological treatment options.
Products and Services
The ClearPoint Neuro, Inc. portfolio includes the ClearPoint system, among other pioneering technologies focused on enhancing the efficacy and safety of neurosurgical interventions:
- ClearPoint System: This integrated system represents a significant advancement in the field of neurosurgery. It is specifically designed for the precise insertion of deep brain stimulation electrodes, biopsy needles, laser catheters, and the infusion of pharmaceuticals directly into the brain. The ClearPoint system facilitates these procedures under real-time MRI guidance, enabling surgeons to perform interventions with improved accuracy and reduced risk to the patient. This system underscores ClearPoint Neuro's commitment to improving the quality of life for patients undergoing neurological treatments by providing a minimally invasive alternative to traditional surgical approaches.
